Animal Antibacterial Peptide Market Analysis – 2024
Browse through Animal Antibacterial Peptide Market report to know what factors will shape the market by 2024: http://www.transparencymarketresearch.com/animal-antibacterial-peptide-market.html
The use of low levels of antibiotics in animal feed as growth promoters and rise in use of antibiotics in animal and human infections are causes of antibiotics resistance among gram negative, gram positive, and bacterial pathogens. The natural and synthetics antibacterial peptides are good candidates for antibiotics alternatives. The natural antibiotics are rich source of proteins as well as amino acids and have less side effects as compared to synthetic antibiotics. They possess synergistic activity with conventional antibiotics and promote wound healing. Domestic animals are good source of antibacterial peptides. The antibacterial peptides are expressed in many polymorphonuclear leukocytes, tissues, macrophages, and mucosal epithelial cells. Antibacterial peptides are preserved in their function, structure, and mechanisms of action. Thus, it is attractive to speculate that synthetic antibacterial peptides or their congeners might be used to prevent or treat infections. Antimicrobial peptides are good applicants for the design of new antimicrobial agents for specific application because of their low propensity for the development of bacterial resistance and natural antimicrobial properties. The major driving factor of antibacterial peptides is their ability to kill multi drug resistance bacteria.
The market of animal antibacterial peptide is segmented on the basis of peptide type, product origin, and geography. On the basis of peptide type, the animal antibacterial peptide market is segmented as linear cationic α-helical peptides, anionic peptides, cationic peptide containing specific amino acid, and anionic & cationic peptides that possess cysteine and form disulfide bonds. Anionic peptides are rich in glutamic and aspartic acids whereas cationic peptides are rich in arginine, phenylalanine, glycine, tryptophan, and proline. These peptides are good candidates for supplements to conventional antibiotic therapy and for development as novel therapeutic agents. These are broad spectrum in nature and possess bactericidal activity. Insect’s peptides are one of the largest groups of antimicrobial peptides. Cecropins constitute the most important host defense system against bacterial infection. By product origin, the animal antibacterial peptide market is segmented into cattle origin, sheep origin, goat origin, pig origin, horse origin, and poultry. The animal antibacterial peptides are derived from above sources.
By geography, the market for animal antibacterial peptide is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to dominate the market. The rise in research is the key driving factor of the animal antibacterial peptide market in North America. Asia pacific is the most progressive region for the animal antibacterial peptide market. The rise in expenditure on animal health care is a key factor responsible for growth of the market. The increasing resistance to conventional antibiotics is likely to be the key driver of the animal antibacterial peptide market during the forecast period. Furthermore, the rise in use of antibiotics to treat various infections and disease in animal feed is projected to fuel the growth of the animal antibacterial peptide market during the forecast period.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Animal Antibacterial Peptide Market by 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18662
Major players operating in the animal antibacterial peptide market include Zoetis, Merck Animal Health, Merial, Elanco (Eli Lilly and Company), Bayer HealthCare, Animal Medics, Biogenesis Bago, and Boehringer Ingelheim Vetmedica. The rising demand for alternatives for conventional antibiotics is estimated to increase the competition between market players of animal antibacterial peptide.
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Animal Antibacterial Peptide Market Analysis – 2024 here
News-ID: 579303 • Views: 311
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment
More Releases for Antibacterial
Magniflex Introduces Antiviral and Antibacterial Collection
Magniflex, the renowned mattress manufacturer from Italy, has always had innovation in its DNA, as the success, accolades, and certifications obtained over the years prove, and the goal has always been to introduce innovative solutions to common issues that affect the quality of our sleep. As a response to the COVID-19 global pandemic, Magniflex conducted scientific and technological research in collaboration with prominent experts in order to produce MagniProtect: an
Global Antibacterial Drugs Market Research Report
This report studies the global Antibacterial Drugs market status and forecast, categorizes the global Antibacterial Drugs market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer AG Pfizer Inc. Sanofi GlaxoSmithKline Plc. (GSK) Merck & Co., Inc. AstraZeneca Johnson and Johnson Bristol
Global Antibacterial Drugs Market: Regional Overview
The global antibacterial drugs market features a fairly competitive landscape and leading players include Allergan, Plc., Novartis AG, Bristol Myers Squibb Company, Johnson and Johnson, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi, Pfizer Inc., Bayer AG, notes Transparency Market Research (TMR). Over the years, the competition in the market is expected to intensify. A number of prominent players are focusing on entering into strategic collaborations and mulling
Antibacterial Drugs Market: Regional & Competitive Analysis
The global antibacterial drugs market, according to TMR, could expand at a CAGR of 1.30% between 2015 and 2023 to achieve a revenue valuation of nearly US$38.9 bn by the final forecast year. Although β-lactams had dominated the market in the past with a larger share, the drug class could lose its share to miscellaneous antibacterials, which are projected to rise at a higher growth rate during the forecast period.
Global Antibacterial Drugs Sales Market Report 2017
Qyresearchreports include new market research report "Global Antibacterial Drugs Sales Market Report 2017" to its huge collection of research reports. The report on global Antibacterial Drugs presents a detailed overview of the current market dynamics and emerging trends and opportunities. Various factors and trends are expected to favorably impact the Antibacterial Drugs market over the forecast period 2017-2022. The study provides comprehensive insights into notable trends and opportunities shaping the market
Antibacterial Drug Development Market Pipeline Review 2017
Antibacterial Therapies Drug Development Pipeline Review 2017 report covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the